Stock Analiz

Silence Therapeutics plc (SLN) financials: revenue, earnings and cash flow

Fiscal 2018–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was -$89M, a net margin of -15851.9%; the best year in this period was 2018 with -$24M.

Over the twelve months to June 30, 2026, revenue was $615000 and net income -$60M.

Free cash flow was -$62M in fiscal 2025 and positive in 2 of the 8 years shown.

Revenue, profit and cash flow by year

Revenue
2019: $32218020192020: $7M20202021: $17M20212022: $22M20222023: $32M20232024: $43M20242025: $5590002025$559000
Net income
2018: -$24M20182019: -$26M20192020: -$44M20202021: -$53M20212022: -$50M20222023: -$54M20232024: -$45M20242025: -$89M2025-$89M
Free cash flow
2018: -$22M20182019: $2M20192020: -$15M20202021: $7M20212022: -$57M20222023: -$50M20232024: -$68M20242025: -$62M2025-$62M
EPS (diluted)
2018: $-0.3820182019: $-0.4220192020: $-0.7120202021: $-0.8520212022: $-0.8120222023: $-0.8720232024: $-0.7320242025: $-1.432025$-1.43

Income statement

Fiscal yearTTM20252024202320222021202020192018
Revenue$615000$559000$43M$32M$22M$17M$7M$322180—
Gross profit—$344000$31M$19M$8M$7M$2M$322180—
Operating income—-$91M-$63M-$64M-$61M-$62M-$49M-$30M-$26M
Net income-$60M-$89M-$45M-$54M-$50M-$53M-$44M-$26M-$24M
EPS (diluted)$-1.27$-1.43$-0.73$-0.87$-0.81$-0.85$-0.71$-0.42$-0.38
R&D—$68M$68M$57M$44M————
Revenue growth—−98.7%+36.7%+46.1%+29.4%+131.3%+2145.3%——

Cash flow

Fiscal yearTTM20252024202320222021202020192018
Operating cash flow-$42M-$62M-$68M-$49M-$57M$9M-$15M$2M-$21M
Capital spending-$907606-$55000-$211000-$56000-$173000-$2M-$697468-$11884-$166400
Free cash flow-$42M-$62M-$68M-$50M-$57M$7M-$15M$2M-$22M
Dividends paid—$0$0$0$0$0$0$0$0
Buybacks—————————
Stock-based pay—$8M$16M$16M$13M$12M$6M$771120$871680

Balance sheet

Fiscal yearTTM20252024202320222021202020192018
Cash—$85M$147M$69M—————
Debt—$160000$117000$346000—————
Equity—$62M$134M$22M$27M$12M$12M$28M$45M
Total assets—$131M$203M$119M—————
Shares (diluted)47M62M62M62M62M62M62M62M62M

Margins and returns

Fiscal yearTTM20252024202320222021202020192018
Gross margin—61.5%72.7%59.3%37.8%39.9%32.4%100.0%—
Operating margin—-16292.8%-146.4%-203.5%-281.9%-369.0%-676.4%-9317.2%—
Net margin-9748.5%-15851.9%-104.7%-171.4%-232.4%-317.4%-614.1%-8025.4%—
FCF margin-6872.5%-11149.6%-156.8%-156.5%-264.2%44.3%-213.0%704.1%—
ROIC—-115.2%-37.3%-227.7%-177.2%-428.9%-357.3%-93.1%-52.6%
ROE—-142.2%-33.8%-246.6%-184.9%-429.3%-359.3%-93.7%-52.5%

Frequently asked questions

What is Silence Therapeutics’s annual revenue?

$559000 in fiscal 2025 and $615000 over the twelve months to June 30, 2026.

How much profit does Silence Therapeutics make?

Net income was -$89M in fiscal 2025 (net margin -15851.9%).

Is Silence Therapeutics’s revenue growing?

No: revenue fell 98.7% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.